A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis (NCT05081557)
Real World Utilization of Upadacitinib in Adult and Adolescent Patients Living With Moderate to Severe Atopic Dermatitis (AD-VISE)
🩺 Plain-English Summary (8th-Grade Level)
Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, important information is missing on the use patterns and outcomes with upadacitinib in a real-world setting. Therefore, the purpose of this observational study is to help inform real-world usage patterns regarding the safety and effectiveness and duration of response of upadacitinib in adolescent and adult AD participants \>=12 years old in the real-world setting. Upadacitinib is an approved drug being developed for the treatment of AD. Around 975 adolescent and adult participants who are prescribed upadacitinib for the treatment of AD in routine clinical practice will be enrolled worldwide. Participants will receive oral upadacitinib as prescribed by their physician. Data from these participants will be collected for approximately 2 years. There will be no additional burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.
Who can join: Review the eligibility criteria below.
Location: Hospital Universitario Austral /ID# 241607 — Pilar, Buenos Aires
Age range: 12 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (140 Sites)
Showing the first 25 of 140 sites.
- Hospital Universitario Austral /ID# 241607 — Pilar, Buenos Aires
- Buenos Aires Skin /ID# 241606 — Ciudad Autonoma de Buenos Aire, Buenos Aires F.D.
- CEDIC Centro de Investigaciones Clinicas /ID# 241605 — Ciudad Autonoma de Buenos Aire, Buenos Aires F.D.
- Instituto de Neumonologia y Dermatologia /ID# 241604 — Ciudad Autonoma de Buenos Aire, Buenos Aires F.D.
- Centro Respiratorio Infantil /ID# 241609 — Rosario, Santa Fe Province
- Hospital Italiano /ID# 241608 — CABA,
- Kingsway Dermatology & Aesthetics /ID# 242276 — Miranda, New South Wales
- Veracity Clinical Research /ID# 242275 — Woolloongabba, Queensland
- Flinders Medical Centre /ID# 242162 — Bedford Park, South Australia
- Sinclair Dermatology - Melbourne /ID# 242163 — East Melbourne, Victoria
- Burswood Dermatology /ID# 243767 — Victoria Park, Western Australia
- Sydney Skin /ID# 242277 — Newtown,
- Medizin am Hauptbahnhof /ID# 246567 — Vienna, State of Vienna
- EZW HAUT Entzuendungszentrum Wien /ID# 246566 — Vienna, State of Vienna
- Ordensklinikum Linz GmbH Elisabethinen /ID# 246565 — Linz, Upper Austria
- Klinikum Wels-Grieskirchen GmbH /ID# 247369 — Wels, Upper Austria
- Dr. Achim Schneeberger /ID# 247370 — Nenzing, Vorarlberg
- Rejuvenation Dermatology - Edmonton Downtown /ID# 240377 — Edmonton, Alberta
- Winnipeg Clinic /ID# 239603 — Winnipeg, Manitoba
- Dr. Irina Turchin PC Inc. /ID# 240358 — Fredericton, New Brunswick
- Karma Clinical Trials /ID# 239602 — St. John's, Newfoundland and Labrador
- NewLab Clinical Research Inc. /ID# 239600 — St. John's, Newfoundland and Labrador
- Dr Melinda Gooderham Medicine Profession /ID# 239745 — Cobourg, Ontario
- Dr. Lyne Giroux Medicine Professional Corporation /ID# 240084 — Greater Sudbury, Ontario
- Lima's Excellence in Allergy and Dermatology Research Inc /ID# 239854 — Hamilton, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.